Antengene to Start Trial of I PAK4/NAMPT Inhibitor in Solid Tumors/NHL

Shanghai Antengene was approved to start a China Phase I clinical trial of ATG-019 in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL). ATG-019 is a novel oral dual PAK4/NAMPT inhibitor that will be administered as a monotherapy or combined with niacin ER. In preclinical tests, ATG-019 showed anti-tumor activity and a superior pharmacokinetics (PK) and safety profile, the company said. Antengene has a Taiwan Phase I clinical trial of ATG-019 underway in the same patient population.   More details.... Stock Symbol: (HK: 6996) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.